Skip to Content

Bausch Health Companies Inc - Stock Quote BHC

Rating as of

Morningstar's Bausch Health Companies Inc Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Bausch Reports Earnings That Disappoints Market, Though Shares Undervalued Considering B & L Value

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Bausch Health reported its last quarterly results as a combined public company, and while sales and earnings generally met expectations, results came in below FactSet consensus. We maintain our $29 fair value estimate, which reflects our standalone value of recently spun-out Bausch & Lomb, and we also maintain our no-moat rating. While our fair value estimate presently accounts for the Bausch & Lomb holding, we intend to remove this adjustment following the planned stock distribution of Bausch & Lomb. In the meantime, however, we view shares as undervalued.

Read Full Analysis

Bausch Health Companies Inc's Company Profile

Business Description

Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.

2150 Saint Elzear Boulvard West
Laval, QC, H7L 4A8, Canada
T +1 514 744-6792
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type
Employees 19,600

Bausch Health Companies Inc's Related News